Literature DB >> 11826869

Bone mineral density and body composition in Noonan's syndrome: effects of growth hormone treatment.

C Noordam1, J Span, R R van Rijn, E Gomes-Jardin, C van Kuijk, B J Otten.   

Abstract

We assessed bone mineral density (BMD) and body composition in children with Noonan's syndrome (NS) before and during growth hormone (GH) treatment. Sixteen children (12 boys, 4 girls) with NS aged 5.8-14.2 (mean 10.0) years were studied for 2 years. Anthropometry, BMD measurements by radiographic absorptiometry and bioimpedance measurements (Akern-BIA 101/S) were performed at baseline and after 3, 6, 12 and 24 months. Daily GH dosage was 0.05 mg/kg. Trabecular volumetric BMD was normal; cortical BMD was in the lower normal range at baseline and slightly increased over the 2 years. Fat free mass and total body water were below normal at the start and increased significantly over the first 3 months, with a slight increment thereafter. Percentage fat mass decreased over the first 6 months and increased thereafter. These findings are comparable to the data on body composition in short normal children and girls with Turner's syndrome treated with GH.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11826869     DOI: 10.1515/jpem.2002.15.1.81

Source DB:  PubMed          Journal:  J Pediatr Endocrinol Metab        ISSN: 0334-018X            Impact factor:   1.634


  2 in total

1.  Physical activity as a preventive measure against overweight, obesity, infections, allergies and cardiovascular disease risk factors in adolescents: AFINOS Study protocol.

Authors:  Oscar L Veiga; Sonia Gómez-Martínez; David Martínez-Gómez; Ariel Villagra; María E Calle; Ascensión Marcos
Journal:  BMC Public Health       Date:  2009-12-19       Impact factor: 3.295

2.  Decreased bone mineralization in children with Noonan syndrome: another consequence of dysregulated RAS MAPKinase pathway?

Authors:  Kiran S Choudhry; Monica Grover; Alyssa A Tran; E O'Brian Smith; Kenneth J Ellis; Brendan H Lee
Journal:  Mol Genet Metab       Date:  2012-04-11       Impact factor: 4.797

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.